Specific IgE Response to Purified and Recombinant Allergens in Latex Allergy by Kurup, Viswanath P. et al.
Marquette University
e-Publications@Marquette
Mathematics, Statistics and Computer Science
Faculty Research and Publications
Mathematics, Statistics and Computer Science,
Department of
8-10-2005
Specific IgE Response to Purified and
Recombinant Allergens in Latex Allergy
Viswanath P. Kurup
Medical College of Wisconsin
Gordon L. Sussman
University of Toronto
Hoong Y. Yeang
Rubber Research Institute of Malaysia
Nancy Elms
Medical College of Wisconsin
Heimo Breiteneder
Medical University of Vienna
See next page for additional authors
Published version. Clinical and Molecular Allergy, Vol. 3, No. 11 (August 2005). DOI. © 2005 Kurup
et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Authors
Viswanath P. Kurup, Gordon L. Sussman, Hoong Y. Yeang, Nancy Elms, Heimo Breiteneder, Siti AM Arif,
Kevin J. Kelly, Naveen K. Bansal, and Jordan N. Fink
This article is available at e-Publications@Marquette: https://epublications.marquette.edu/mscs_fac/264
BioMed Central
Page 1 of 9
(page number not for citation purposes)
Clinical and Molecular Allergy
Open AccessResearch
Specific IgE response to purified and recombinant allergens in latex 
allergy
Viswanath P Kurup*1,2, Gordon L Sussman3, Hoong Y Yeang4, Nancy Elms1, 
Heimo Breiteneder5, Siti AM Arif4, Kevin J Kelly1, Naveen K Bansal6 and 
Jordan N Fink1
Address: 1Allergy-Immunology Division, Medical College of Wisconsin Milwaukee, WI, USA, 2Research Service, V A Medical Center, Milwaukee, 
WI, USA, 3University of Toronto, Ontario, Canada, 4Biotechnology and Strategic Research Unit, Rubber Research Institute of Malaysia, Kuala 
Lumpur, Malaysia, 5Department of Pathophysiology, Medical University of Vienna, Vienna, Austria and 6Department of Mathematics, Marquette 
University, Milwaukee, WI, USA
Email: Viswanath P Kurup* - vkurup@mcw.edu; Gordon L Sussman - gsussman@rogers.com; Hoong Y Yeang - hyyeang@lgm.gov.my; 
Nancy Elms - nelms@mcw.edu; Heimo Breiteneder - Heimo.Breiteneder@meduniwien.ac.at; Siti AM Arif - sitiarija@lgm.gov.my; 
Kevin J Kelly - kkelly@mcw.edu; Naveen K Bansal - naveen.bansal@marquette.edu; Jordan N Fink - jfink@chw.org
* Corresponding author    
Abstract
Background: In recent years, allergy to natural rubber latex has emerged as a major allergy among certain
occupational groups and patients with underlying diseases. The sensitization and development of latex allergy has
been attributed to exposure to products containing residual latex proteins. Although improved manufacturing
procedures resulted in a considerable reduction of new cases, the potential risk for some patient groups is still
great. In addition the prevalent cross-reactivity of latex proteins with other food allergens poses a major concern.
A number of purified allergens and a few commercial kits are currently available, but no concerted effort was
undertaken to evaluate them.
Methods: We studied 11 purified latex allergens, Hev b 1 to Hev b 10, and Hev b 13 along with several crude
allergen extracts and two commercial ImmunoCAP assays to evaluate specific IgE antibody in the sera from latex
allergic patients and controls. Health care workers and spina bifida patients with clinical symptoms of latex allergy,
spina bifida patients without latex allergy, and non-atopic health care workers have been studied.
Results: The results suggest that Hev b 2, 5, 6, and 13 together identified over 80 percent health care workers
with latex allergy, while Hev b 6 along with Hev b 1 or 3 detected specific IgE antibody in all sera studied from
patients with spina bifida and latex allergy. The ImmunoCAP results using both Hev b 5 amplified and non-
amplified closely agreed with the clinical diagnosis of latex allergy in health care workers and in spina bifida.
Conclusion: Although the purified allergens and crude extracts reacted diversely with IgE from different patient
groups, the results indicated that use of certain combinations of purified recombinant antigens will be useful in
commercial kits or in in-house assays for detecting specific IgE antibody in the sera. The results suggest that a
combination of Hev b 2, 3, 5, 6, and 13 together detected specific IgE in 80% of the sera from latex allergic patients.
Both ImmunoCAPs correctly identified over 95% of latex allergic patients, however, showed reactivity with a few
normal control subjects
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Background
During the 1980's and 90's, allergy to natural rubber latex
had posed serious concerns, particularly in certain occu-
pational groups exposed to latex allergens [1-4]. Among
these occupational groups, health care workers (HCW)
and patients with spina bifida (SB) constitute the two
major populations exposed to various natural rubber latex
products and have a high frequency of manifestations of
latex allergy. Sensitization and the development of latex
allergy have been attributed to the exposure to products
containing residual latex proteins. Although considerable
advances have been made in the diagnosis and patient
care, no standardized tests or reagents are currently avail-
able that can be reliably and safely used in the diagnosis
of latex allergy [3-5]. A crude latex extract from a clone of
Malaysian rubber tree Hevea brasiliensis, clone RRIM 600
has been made available for evaluation and was proposed
as a candidate allergen for skin test and in in vitro specific
serum IgE assays [6,8]. This extract has been widely tested
as a skin-testing reagent and has been evaluated by the
multi-center latex skin testing study task force with suc-
cess, although the clone is classified as an unstable pheno-
type with variability in the latex composition [9]. Crude
extracts are not appropriate candidates as standardized
antigens due to their variability, lack of dependability,
irrelevant cross reactivity, and questionable safety in in
vivo use such as skin testing. In recent years a number of
genes encoding relevant antigens from natural rubber
latex have been cloned and the proteins expressed [10].
However, only a few studies have been carried out to eval-
uate these conventionally purified or cloned and
expressed allergens [5]. Currently, there are 13 Hevea latex
allergens recognized by the IUIS Allergen Nomenclature
Committee [10].
In recent years, several semi-automated in vitro assays have
been developed commercially for detecting latex specific
IgE antibody. In the present study, we investigated latex
specific IgE in the sera of patients and controls using puri-
fied and crude latex allergens prepared from non-ammo-
niated Malaysian natural rubber latex extracts and glove
extracts. The extracts were evaluated in an ELISA and the
results compared with ImmunoCAP, a widely used semi-
automated commercial assay for IgE antibody. The puri-
fied antigens reacted diversely with different patient sera
by ELISA and no single allergen reacted with IgE from all
proven latex allergic patients studied. However, Hev b 2,
5, 6, and 13 together and Hev b 6 with Hev b 1 or 3 dem-
onstrated IgE from majority of HCW patients and spina
bifida patients respectively. The ELISA results were com-
parable to ImmunoCAP, but the latter agreed more closely
with clinical diagnosis.
Methods
Patients and controls
A total of 36 HCW were studied, of which 10 had no clin-
ical symptoms of latex allergy; the remaining 26 subjects
had clinically proven latex allergy [3,5]. Among the 21 SB
patients studied, 13 had clinical latex allergy [11]. Latex
allergy in health care workers was diagnosed by (a) a his-
tory of skin and respiratory symptoms often progressing
from contact dermatitis through urticaria to asthma and
anaphylaxis on latex contact, usually with latex glove
powder inhalation, or (b) immediate wheal and flare skin
reaction to latex glove antigens, (c) a history of reaction to
cross-reactive latex antigens such as bananas or other
fruits, and/or (d) serum IgE antibodies to latex glove
extracts carried out by ELISA. Latex allergy in SB patients
was diagnosed by a history of perioperative anaphylaxis
and/or the demonstration of respiratory symptoms on
latex glove powder contact, and/or the demonstration of
antibody to latex antigens and a history of cross-reaction
to food allergens [11]. All sera were evaluated for latex
specific IgE antibody using a Malaysian non-ammoniated
latex extract, two glove extracts routinely used in our lab-
oratory to confirm the diagnosis [11,12].
Latex Antigens
Four crude latex extracts and 11 purified and recombinant
allergens from H. brasiliensis latex were used for in vitro
studies of latex specific serum IgE antibody. The purified
allergens used in the study are listed in Table 1. All anti-
gens were used in an ELISA to evaluate latex specific IgE
antibody in sera of patients with latex allergy and normal
healthy controls [5,11,12]. Latex collected after tapping H.
brasiliensis trees (rubber trees) was shipped frozen to the
laboratory from Malaysia. The clear serum phase of the
latex was collected after centrifugation of the coagulated
latex as described previously [5,12,13]. This extract desig-
nated as Malaysian non-ammoniated latex (MNA) was
characterized and used in ELISA as described previously
[5]. Another crude latex extract was from clone RRIM 600
and was obtained from Greer Laboratory [7]. Two latex
glove extracts were also used in the study. These gloves
were selected from two different manufacturing sources,
one with more extractable protein, while the other one
with a lower latex protein content. The allergens were
extracted from pieces of latex gloves by stirring with PBS
in a flask for 15 min at room temperature as previously
described [14,15]. We used two different ImmunoCAPs;
in one the crude latex was used to make the CAPs, while
in the other in addition to the regular CAP, Hev b 5 was
also supplemented. This modification was devised to rem-
edy the lack of Hev b 5 in the clotted serum of rubber
latex.
Three of the allergens Hev b 2, Hev b 4, and Hev b 13 were
purified from latex by the Malaysian laboratory (HYY) as
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previously described [5,16,17]. The genes for Hev b 1, 3,
5, 6, 7, 8, 9, and 10 were cloned from cDNA libraries and
Hev b 1, 3, 5, and 6 were expressed in the Medical College
of Wisconsin laboratory (VPK), while Hev b 7, 8, 9, and
10 were cloned and expressed in the University of Vienna
laboratory (HB) [18,27].
Characterization of latex antigens
The protein profile of the extract was studied by sodium
dodecyl sulfate polyacrylamide gel electrophoresis. Elec-
trophoresis was carried out by loading 10 micrograms of
proteins on a 12% SDS polyacrylamide mini gel and run-
ning at 200 mv/cm for 40 to 50 minutes [5]. The gels were
stained with Coomassie brilliant blue R-250 and the
stained bands in the gel were compared and the molecular
sizes ascertained. The reactivity of antigens to serum IgE
was studied using pooled sera from HCW and SB patients
with latex allergy and controls by ELISA and Western blot.
Latex specific IgE by ELISA
The MNA, Clone RRIM 600, glove extract antigens, and
purified latex proteins were coated at a concentration of 5-
µg protein/ml. All dilutions and coating concentrations of
the antigens and reagents were derived from checkerboard
titration using latex positive and negative sera. The ELISA
was performed as previously described [5]. Briefly, one
hundred micro liters of the preparations were added to
the wells of polystyrene micro titer plates (Immunolon II
HB, Therma Lab Systems, Franklin, MA). The plates were
incubated at room temperature for 3 hours, followed by a
further incubation at 4°C overnight. After washing the
plates with PBS, containing 0.05% Tween 20 (PBS-T), the
wells were blocked with 0.5% BSA in PBS-T. The wells
were again washed and 100-µl of 1:25 dilution of the
serum added to each well, incubated at room temperature
for 3 hours, and washed as before. One hundred-µl of
biotinylated mouse, anti-human IgE monoclonal anti-
body (Zymed Laboratories, Inc., San Francisco, CA) was
added to each well and the plates were incubated for 1
hour at room temperature, washed as before and 100 µl of
1:2000 dilution of streptavidin peroxidase was added to
the wells. This was followed by incubation for 30 minutes
and washing again. Finally, the peroxidase activity was
developed with o-phenylenediamine substrate in citrate
buffer. The color was developed for 15 minutes in a dark
chamber and the reaction stopped by the addition of 25
µl of 2N H2SO4 solution. The color was read in an ELISA
plate reader using a 490 nm filter (Molecular Devices;
Sterling, VA). The optical density (O.D) values were cor-
rected by subtracting the blank values and the average of
three wells was taken. A value exceeding mean plus two
standard deviation (SD) of HCW and SB patients without
latex allergy was taken as a cut off value for positivity.
ImmunoCAP
The Pharmacia ImmunoCAP was used to demonstrate
latex specific IgE in the sera of patients and controls
according to the instructions of the manufacturer. Both
Hev b 5 amplified (rk82) and non-amplified (k82)
ImmunoCAPs were used. The protocol of the manufac-
turer was followed, and a value of 0.35 kUA/L or more was
considered positive.
Statistical analysis
The mean O.D values for all allergens were calculated and
the results were analyzed by the multivariate analysis of
variance (MANOVA). A P-value of 0.05 was considered
significant. When a significant difference was detected, a
stepwise discriminant analysis was also performed to
select the significant allergens that delineate the positive
and negative groups by their reactivity or non-reactivity
with IgE by ELISA. The variables with P-value of < 0.05
were chosen as the significant variables, while the varia-
bles with P-value > 0.20 were removed at each step of the
Table 1: Purified Latex Allergens and their Characteristics
Allergen Biochemical Function Alternate Name Molecular Size kDa Significance in the 
Diagnosis
Hev b 1 Biosynthesis of polyisoprene Rubber elongation factor 14.9 SB
Hev b 2 Beta 1-3-glucanase defense protein - 35.1 HCW
Hev b 3 Biosynthesis of polyisoprene - 22.3 SB
Hev b 4 Micro helix protein - 50–57 -
Hev b 5 Structural protein 16 HCW
Hev b 6 Plant defense Prohevein 20 SB/HCW
Hev b 7 Esterase inhibitor of polyisoprene Patalin 42.9 -
Hev b 8 Profilin Profilin 13.9 -
Hev b 9 Enolase 47.7 -
Hev b 10 Manganese superoxide dismutase - 22.9 -
Hev b 13 Esterase - 43 HCW
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discriminant analysis. Using all the significant allergens,
Fisher discriminant functions for the latex allergic and
non-allergic HCW and SB subjects were calculated. Based
on this, each case was assigned two Fisher discriminant
scores, one for the latex allergic group and the other one
for the non-allergic group. Each subject was classified into
a group (latex allergic or non-allergic) based on the higher
corresponding Fisher discriminant score value as the case
may be [5,28].
Results
Characteristics of the antigens
The protein profiles using sodium dodecyl sulfate polyacr-
ylamide gel electrophoresis (SDS-PAGE) of MNA, Clone
RRIM600 and the various purified latex antigens are
shown in Figure 1. MNA and Clone RRIM600 showed a
number of bands in SDS-PAGE, while most of the purified
allergens used in the study showed single bands. A few of
the purified antigens showed additional weak bands in
the gel, the immunoblots of the protein reacted with IgE
from latex allergic patients showing IgE binding with only
the major bands and not with the weak bands. The two
glove extracts showed very weak bands. The Western blots
of both glove extracts, MNA, and Clone RRIM600 showed
multiple reactive bands with the pooled latex allergic
patient sera, but not with the normal control sera.
Latex specific IgE in the sera
Of the 36 HCW evaluated, 26 were symptomatic with urti-
caria or asthma on latex allergen exposure; 10 subjects had
no symptoms on exposure to latex products in the health
care workplace. All 36 subjects included in this study were
exposed to latex proteins present in gloves or other latex
products. The IgE reactivity of the sera from HCW patients
to11 purified latex antigens by ELISA is shown in Figure 2.
Hev b 2, 4, 5, 6, and 13 showed significant binding to IgE
in the patients' sera, while Hev b 1, 3, 7, 8, 9, and 10 failed
to show significant binding to IgE compared to controls
(Fig. 2). In ImmunoCAP, 25/26 HCW patients showed
0.35 kUA/L or more, while one normal subject without
latex allergy was also positive (Fig. 3). One out of the 26
patients who failed to show latex specific IgE by the
ImmunoCAP showed strong reactivity with Hev b 5 by
ELISA and Hev b 5 amplified ImmunoCAP. On the other
hand, one patient negative to all crude antigens and most
purified antigens showed strong reactivity to Hev b 5 and
amplified Hev b 5 ImmunoCAPs. This patient also
showed significant IgE to Hev b 5 and Hev b 13 by ELISA.
The solitary HCW patient that showed strong reactivity
with Hev b 1 and Hev b 3 also reacted with most other
latex allergens studied. Hev b 7, 8, 9, and 10 invariably
showed only very weak reactions with specific IgE in the
sera of most patients tested, while Hev b 2, Hev b 6, and
Hev b 13 consistently showed high levels of IgE in more
patients compared to other purified allergens. Three out
of 10 normal subjects also showed IgE to Hev b 2 in their
sera, but the levels were comparatively lower than those
detected in patients. Hev b 13 also failed to react with two
latex allergic patients, but did not show any reactivity with
the normal controls.
The reactivity of various allergens to the IgE of SB patients
are shown in Figure 4. All 13 latex allergic patients showed
significantly elevated IgE levels by both ImmunoCAPs
and ELISA using crude latex extracts, while none of the
non-allergic SB showed any reactivity (Fig. 3). Both Hev b
1 and Hev b 3 demonstrated strong reactivity with IgE of
11/13 patients; the remaining two patients had low levels
of IgE against these two allergens. Hev b 6 demonstrated
strong IgE binding to all but one SB patient with latex
allergy, but had no reactivity with SB patients without
latex allergy. Three patients each failed to react with Hev b
5 and Hev b 13, while only three showed binding of IgE
to Hev b 7. Hev b 8, 9 and 10 failed to show binding with
any of the patients or control sera. None of the SB patients
without latex allergy showed any significant reactivity
with IgE to any of the latex allergens except Hev b 2, which
showed strong reactivity with only one patient.
The reactivity of HCW and SB sera against the four crude
antigens are shown in Figure 5A and 5B. Both NRL extracts
reacted strongly with both SB and HCW, with Clone
Sodium dodecyl sulfate polyacrylamide gel electrophoresis profile of lat x allergensFigure 1
Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
profile of latex allergens. Allergens (10 µg) were subjected to 
electrophoresis in 12% SDS-Gel and stained with Coomassie 
brilliant blue. 1 – Molecular weight standards; 2–12 – Hev b 1 
to 10 and Hev b 13; 13 – Crude latex (MNA); 14 – RRIM 
Clone 600 latex.
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RRIM600 showing more reactivity with HCW patients.
Among the crude extracts studied, Glove 1 invariably
showed less reactivity. All four antigens showed reactivity
with the sera from a few control subjects.
The binding of IgE to allergens Hev b 1 to Hev b 6 and Hev
b 13 showed a significant difference (P < 0.05) between
SB patients with and without latex allergy when studied
individually. Hev b 7 to Hev b 10 failed to show any
significant IgE binding reactivity between these two
groups. Among the HCW patients with latex allergy stud-
ied, strong reactivity was detected only with Hev b 2, Hev
b 5, Hev b 6, and Hev b 13. When all 11 purified latex pro-
teins were used together and analyzed the data by
MANOVA, a significant difference was detected with latex
allergic and non-allergic subjects from both HCW and SB
groups (P < 0.05).
Stepwise discriminant analysis of the ELISA data from SB
patients selected Hev b 1, Hev b 3, and Hev b 6 and
together these antigens delineated all the latex allergic and
non-allergic subjects. The Fisher discrimination function
for the positive group is -10.549 + 11.569 Hev b 1 -9.189
Hev b 3 + 5.443 Hev b 6, and for the negative group is -
0.694 + 0.098 Hev b 1 -0.068 Hev b 3 + 0.027 Hev b 6. All
the SB subjects studied could be classified into latex aller-
gic or non-allergic, and the specificity and sensitivity were
found to be 100% by ELISA using these allergens.
Anti-latex IgE antibodies in the sera of HCW patientsFigure 2
Anti-latex IgE antibodies in the sera of HCW patients. IgE antibody against various purified latex allergens in the sera of health 
care workers with latex allergy and those with no clinical symptoms of latex allergy were studied by ELISA.
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The Stepwise discriminant analysis on HCW workers
selected only Hev b 6 as the major allergen, perhaps due
to the fact that this protein is the major allergen with
marked specificity. The Fisher discriminant function for
the latex allergic patient group when Hev b 6 alone is used
is -1.511 -1.627 Hev b 6, and for the non-allergic group is
-0.694 + 0.063 Hev b 6. This analysis correctly classified
17 out of 26 patients as having latex allergy and all 10
HCW subjects without symptoms. However, Hev b 2, Hev
b 5, and Hev b 13 also showed significant reactivity and
hence, discriminant analysis of the IgE binding of Hev b
2, Hev b 5, Hev b 6, and Hev b 13 was also carried out. The
sensitivity and specificity using only Hev b 6 or using Hev
b 2, Hev b 5, Hev b 6, and Hev b 13, and using all aller-
gens Hev b 1 to Hev b 13 were carried out for all patients
and the results indicate a sensitivity of 65 to 85% and a
specificity of 100% (Table 2).
Discussion
The results indicate that crude NRL allergens including an
extract from Clone RRIM600 demonstrate strong reactiv-
ity with IgE from latex allergic HCW patients. Both glove
extracts, in spite of their differences in protein content and
failure to show distinct bands in SDS-PAGE, demon-
strated similar reactivity as shown by MNA and Clone
RRIM600 with both groups of patients. The single patient
negative by unamplified ImmunoCAP reacted strongly to
the amplified ImmunoCAP with Hev b 5 indicating that
Hev b 5 is important for the diagnosis of some of the
HCW patients with latex allergy. None of the other puri-
fied latex allergens studied reacted with IgE from this
patient. Our results indicate that Hev b 1, 3, 4, and 7
through 10 have little or no value in the demonstration of
IgE in HCW patients with latex allergy. In a previous
study, we have shown that Hev b 2, 6, and 7 were useful
in demonstrating IgE in the sera of HCW patients with
latex allergy [5]. Since we did not test Hev b 5 and 13 in
the previous study, the present results indicate a more
complete representation of all the relevant latex allergens
and their reactivity with the sera from different groups of
patients and controls. The results of the present study sug-
gest the usefulness of Hev b 2, 5, 6, and 13 together in the
diagnosis of latex allergy in HCW.
SB patients with latex allergy showed antibody responses
to a different set of latex allergens. Both ELISA and Immu-
noCAP showed strong agreement in demonstrating latex
specific IgE in the sera of most of these patients. The find-
ings indicate that a combination of Hev b 6 and Hev b 1
or 3 would demonstrate specific IgE in the sera of all
patients with SB and latex allergy.
Although crude latex antigens are efficient in demonstrat-
ing IgE antibodies in latex allergic patients, such extracts
are not appropriate as standardizable allergen reagents
due to the inherent variability, complexity of allergenic
components, and in the presence of cross reactive
allergens. The present study suggests that by selecting
significant antigens and by reconstituting known
amounts of purified allergens, it may be possible to obtain
standardizable preparations to demonstrate IgE antibody
in the sera of HCW and SB patients with latex allergy.
From the present study and from previous multi-center
studies, it has been shown that the presence of latex spe-
cific IgE in HCW patients' sera can be demonstrated using
a mixture of Hev b 2, 5, 6, and 13 and in SB patients with
latex allergy by the use of Hev b 6 along with Hev b 1 or
Hev b 3. It is not possible to derive a cut-off value for
delineating the allergic patients from normal controls due
to the high variability in the responses of the patients.
However, additional patients may be studied before
finally selecting the allergens and their proportions in the
mixture for a more standardizable reagent and for devis-
ing a delineation titer.
The present study suggests the need to develop more spe-
cific reliable and reproducible allergen preparations for in
vitro detection of latex allergen specific IgE. Kim and cow-
orkers demonstrated that specific IgE levels to latex
Latex specific IgE antibody in the sera of spina bifida (SB) p ients and health care workersFigure 3
Latex specific IgE antibody in the sera of spina bifida (SB) 
patients and health care workers. Health care workers 
(HCW) and spina bifida (SB) patients with and without latex 
allergy were studied for specific IgE by ImmunoCAPs, regular 
(k82) and ImmunoCAPs amplified with Hev b 5 (rk82).
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allergens in the sera of patients were symptom dependent
and that patients with asthma showed higher levels of spe-
cific IgE compared to those with dermatitis alone [29,30].
Although other investigators demonstrated false positives
and false negative reactions with ImmunoCAP, Alastat
and HY-TEC methods, in the present study our results
were more clear -cut with less false positive and false neg-
ative reactions [7,8]. In the present study, we have
observed a more stronger reactivity with patient serum by
Hev b 5 complemented ImmunoCAP compared to regular
ImmunoCAP. However, the Hev b 5 amplified CAPs also
showed more reactivity with normal control subjects
without latex allergy. Moreover, the reactivities of HCW
and SB patients' serum IgE with the purified antigens were
more consistent than with crude latex extracts and no false
reactivity was detected. Taken together, the present results
indicate that ImmunoCAP system using purified relevant
allergens, could be more dependable and reliable in in
vitro demonstration of latex allergen specific IgE in the
sera of latex allergic patients. The results suggest that a
combination of Hev b 2, 3, 5, 6, and 13 would demon-
strate IgE antibody in the majority of latex allergic
patients.
Conclusion
The results indicate that ImmunoCAP, particularly ampli-
fied with Hev b 5, was useful in demonstrating specific IgE
in the sera of latex allergic patients. When all purified latex
allergens were used together in ELISA, about 89% of
patients with latex allergy were correctly identified. We
conclude from these results that selection of significant
recombinant allergens and reconstitution of these
IgE antibody against various purified latex allergens in SB patientsFigure 4
IgE antibody against various purified latex allergens in SB patients. The sera of spina bifida patients with latex allergy and those 
without clinical symptoms of latex allergy were studied for the presence of latex specific IgE using recombinant latex allergens 
by ELISA.
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purified antigens in immunoassays, such as ELISA, will
provide standardizable reagents for demonstrating spe-
cific IgE in the sera of patients with latex allergy. These
selected purified allergens can be used for more reliable
results in automated assays such as ImmunoCAP.
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IgE reactivity of HCW and SB patients to latex and glove extract antigensFigure 5
IgE reactivity of HCW and SB patients to latex and glove extract antigens. Latex antigens from Hevea brasiliensis, Clone RRIM 
600 and extracts from two examination gloves were studied for IgE binding using sera from spina bifida and health care work-
ers suing ELISA.
Table 2: Sensitivity and specificity of purified latex allergens in the diagnosis of latex allergy in health care workers (HCW)
Latex Allergens Specificity Sensitivity Overall Correct Agreement
Hev b 6 100% 65.40% 75%
Hev b 2, 5, 6, & 13 100% 73.1% 80.6%
All allergens Hev b 1 to Hev b 13 100% 84.6% 88.9%
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